Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities - 05/10/20

Key words : Acute respiratory syndrome, adverse drug reactions, coronavirus, COVID-19, drug allergy, drug hypersensitivity, remdesivir, SARS-CoV-2
El texto completo de este artículo está disponible en PDF.
Esquema
Disclosure of potential conflict of interest: Z.-R. M. Thomas has received funding for congress attendance from Sanofi. D. Jamiolkowski has received funding for congress attendance from Stallergenes. E. Steveling-Klein has a transfer of value agreement with Bencard and has received funding for congress attendance from ALK. K. S. Hofmeier has received funding from Allergopharma, Sanofi-Aventis, Shire, and Novartis. K. Hartmann has received research funding from Euroimmun and consultancy or lecture fees from Allergopharma, ALK-Abelló, Blueprint, Deciphera, Menarini, Novartis, and Takeda. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 146 - N° 4
P. 786-789 - octobre 2020 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.